Fertility· August 19, 2026· 6 min read

GLP-1 Medications and Fertility: What to Know

Ozempic, Wegovy, Zepbound and fertility: how GLP-1s affect ovulation, the birth control interaction most patients miss, and washout before pregnancy.

You may have seen the term "Ozempic babies." Women who had struggled to conceive for years, or who believed they couldn't, found themselves unexpectedly pregnant after starting a GLP-1 medication.

The stories are real, and there are two separate explanations behind them. One is that these medications can restore ovulation in women who weren't ovulating reliably. The other is that one of these drugs measurably interferes with oral birth control, in a way many patients are never told about.

Both matter if you're on a GLP-1 and thinking about pregnancy, in either direction.

Here is what the evidence and the FDA labeling actually say.

First, the terminology

GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes and now widely prescribed for weight management. The ones you're most likely to be taking:

Semaglutide, sold as Ozempic, Wegovy, and Rybelsus
Tirzepatide, sold as Mounjaro and Zepbound, which acts on both GLP-1 and GIP receptors
Liraglutide, sold as Victoza and Saxenda

The differences between them matter more than most patients realize, particularly around contraception.

Why these medications can restore fertility

For women with polyendocrine metabolic ovarian syndrome (PMOS), the condition formerly known as PCOS, the connection is direct.

PMOS involves insulin resistance and hormone disruption that interfere with regular ovulation. Weight reduction and improved insulin sensitivity can restore ovulatory cycles, which is why lifestyle intervention has long been a first-line recommendation.

GLP-1 medications produce both effects. Research has found that in women with obesity and PMOS, these medications improve ovulation rates and spontaneous pregnancy rates compared with metformin alone. Some studies also suggest GLP-1 receptor signaling may act on ovarian tissue directly, affecting granulosa cell function and androgen levels, beyond the effects of weight loss alone.

The practical result: a woman who had irregular or absent periods may begin ovulating again, sometimes within months, and sometimes without realizing it has happened.

An important caveat. Reviews of the current evidence position these medications as time-limited tools for metabolic optimization before conception, not as fertility treatments. The optimal timing, dose, and duration for improving fertility haven't been established, and the reproductive evidence is considerably less settled than the metabolic evidence. No major professional society currently recommends prescribing them for the purpose of achieving pregnancy.

The birth control interaction: this differs by drug

This is the part most often missed, and the distinction is specific.

Tirzepatide (Mounjaro, Zepbound) does interact with oral contraceptives. The FDA prescribing information states that tirzepatide may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. In the labeled study, giving a combined oral contraceptive with a single 5 mg dose of tirzepatide reduced peak concentrations of ethinyl estradiol by 59%, norgestimate by 66%, and norelgestromin by 55%.

The label's instruction is explicit. Patients using oral hormonal contraceptives should switch to a non-oral method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase.

That second part is the one people miss. It applies every time your dose goes up, not only when you start.

Semaglutide labeling does not carry this instruction. Oral contraceptives were evaluated in semaglutide's drug interaction studies, and the FDA labels for Ozempic and Wegovy do not include a backup contraception requirement.

If you are taking any GLP-1 and relying on an oral contraceptive, this is worth confirming against your specific product's label with your prescriber. The class is often discussed as though the drugs are interchangeable. On this point, they are not.

If you are planning a pregnancy

The FDA labels for both Ozempic and Wegovy state that patients should discontinue semaglutide at least 2 months before a planned pregnancy.

The reason is pharmacologic rather than a specific known harm. Semaglutide has an elimination half-life of approximately one week, and the label notes it remains in circulation for roughly 5 to 7 weeks after the last dose. The two-month recommendation builds in a margin beyond that.

Washout guidance varies by product, so check the label for the specific medication you take rather than assuming the semaglutide timeline applies.

This creates a real planning problem. Stopping the medication two months before trying to conceive often means regaining some weight during exactly the window when metabolic health matters most. There is no clean answer to this, and it is a conversation worth having with a physician who understands both sides of it rather than deciding alone.

What is known about exposure during pregnancy

Many pregnancies on these medications are unplanned, so this question comes up often, usually after the fact.

Animal studies showed adverse developmental effects, including structural abnormalities and reduced fetal growth, which is the basis for the labeling caution.

Human data has been more reassuring, with important limits. A 2026 systematic review and meta-analysis pooling seven cohort studies covering more than 40,000 exposed pregnancies found that maternal GLP-1 exposure was not associated with a statistically significant increase in congenital malformations, and first-trimester exposure did not significantly increase the risk of major malformations. Other analyses have found no significant increase in stillbirth, miscarriage, small-for-gestational-age birth, or preterm birth.

The researchers themselves are careful here, and so are we: these are observational studies, not randomized trials. The authors state directly that the findings should not be interpreted as proof of safety, and that larger prospective studies are needed.

What this means practically. If you discover you are pregnant while taking a GLP-1, that is a reason to contact your physician promptly, not a reason to panic. The current human evidence does not show the harm the animal data suggested. Do not stop or continue any prescribed medication based on an article. Call the person who prescribed it.

What to do

If you're on a GLP-1 and don't want to be pregnant: find out whether your specific medication carries the oral contraceptive warning. If you take tirzepatide and rely on the pill, use a backup or non-oral method for 4 weeks after starting and after every dose increase.

If you're on a GLP-1 and want to be pregnant: talk with your physician about washout timing before you start trying, not after. Two months is the labeled guidance for semaglutide, and planning for it is easier than reacting to it.

If you have PMOS and are considering a GLP-1: it may improve your metabolic picture and your ovulation, but it isn't a fertility treatment, and the preconception washout has to be part of the plan from the beginning.

If you're already pregnant: contact your physician promptly.

Where to start

If you have PMOS, irregular cycles, or you're weighing how a GLP-1 fits into your plans for a family, these decisions are easier to make with someone who handles both the metabolic and reproductive sides.

Dr. Subodh Chauhan is board certified in OB/GYN and Reproductive Endocrinology, and sees patients in Houston and Sugar Land.

Schedule a consultation

This article is for informational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Do not start, stop, or change any medication based on this article. Always seek the guidance of a qualified healthcare provider with any questions regarding your health, your medications, or your pregnancy.

Sources

Ready to talk it through with Dr. Chauhan?

Most new patients are seen within a week at our Houston or Sugar Land office.

Book your consultation (713) 405-1370

Keep reading

Take The First Step

New Patient Registration Form

Administrative use only. Please do not include medical complaints or diagnoses.

12Step 1 of 2

Your information

First name *

Middle name

Last name *

Date of birth *

Email *

Phone *

Sex assigned at birth *

Street address *

City *

State *

Zip *